Apr 07, 2020
To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units
Oct 10, 2019
Ardelyx to Host Analyst Day in New York
Mar 07, 2019
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Jan 15, 2019
WG Critical Care (WGCC) Expands Portfolio With Unique Product
Dec 11, 2018
Groundbreaking NYU Winthrop Study Shows Promise for Correcting Common Misdiagnoses of Hyponatremia That Can Cause Critical Patients to Deteriorate Further
Dec 10, 2018
Hypoparathyroidism Treatment Market Will Reach at a CAGR of 8% From 2018 to 2026
Oct 26, 2018
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Sep 10, 2018
FDA Designates AliveCor's Bloodless Hyperkalemia Test a "Breakthrough Device"
Aug 29, 2018
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
Apr 11, 2018
New Study: American Formulation of Oral Urea Effective Treatment for Abnormally Low Blood Sodium Levels
Sep 26, 2017
New Survey of People with Chronic Kidney Disease Finds High Potassium is Among Top Health Concerns
Aug 31, 2017
European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis
Jun 23, 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis